The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity. The total number of weeks of the study is up to approximately 22 weeks (5.5 months).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
21
PF-07976016 oral tablets
PF-06882961 oral tablets
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Steady state area under the concentration-time profile for PF-07976016
Time frame: From 0 Hours to 24 Hours following steady-state dose
Steady state maximum observed concentration (Cmax) for PF-07976016
Time frame: From 0 Hours to 24 Hours following steady-state dose
Steady state area under the concentration-time profile danuglipron
Time frame: From 0 Hours to 24 Hours following steady-state dose
Steady state maximum observed concentration (Cmax) for danuglipron
Time frame: From 0 Hours to 24 Hours following steady-state dose
Number of participants with treatment emergent adverse events
Time frame: First dose (Day 1) through 28-35 days after final dose (approximately 18 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.